Diana Isaacs
Psychiatric/Mental Health · Austintown, OHNPI 1265050538
Payments from drug & device makers
Across 947 payments — averaging $54.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$33K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Insulet Corporation$2K
- Almatica Pharma LLC$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $10K from 24 others
What the payments were for
- Speaking & faculty fees$31,79061%
- Travel & lodging$2,1774%
- Food & beverage$17,82634%
- Education$2030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 227 | $32,794 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 91 | $2,302 |
| Insulet Corporation | 1 | $2,100 |
| Almatica Pharma LLC | 24 | $1,996 |
| Otsuka America Pharmaceutical, Inc. | 92 | $1,813 |
| Teva Pharmaceuticals USA, Inc. | 91 | $1,368 |
| Medtronic | 13 | $1,120 |
| Lundbeck LLC | 87 | $1,097 |
| Alkermes, Inc. | 34 | $1,007 |
| Axsome Therapeutics, Inc. | 40 | $998 |
| Johnson & Johnson | 29 | $929 |
| Neurocrine Biosciences, Inc. | 36 | $757 |
| Takeda Pharmaceuticals U.S.A., Inc. | 46 | $685 |
| E.r. Squibb & Sons, L.L.C. | 25 | $632 |
| Vanda Pharmaceuticals Inc. | 25 | $492 |
| Supernus Pharmaceuticals, Inc. | 25 | $453 |
| Corium, LLC | 28 | $356 |
| Sequel Med Tech, LLC | 2 | $313 |
| Dexcom, Inc. | 2 | $158 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $113 |
| Mannkind Corporation | 3 | $94 |
| Noven Therapeutics, LLC | 5 | $87 |
| Tris Pharma Inc | 4 | $73 |
| Sunovion Pharmaceuticals Inc. | 5 | $59 |
| Xeris Pharmaceuticals, Inc. | 1 | $54 |
| Eisai Inc. | 3 | $49 |
| Collegium Pharmaceutical, Inc. | 3 | $44 |
| Merck | 1 | $19 |
| Sage Therapeutics, LLC | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$29,185
- Omnipod$2,100
- LOREEV XR$1,659
- MINIMED 770G$742
- CAPLYTA$595
- LYBALVI$408
- INVEGA SUSTENNA$368
- ABILIFY MAINTENA$344
- TWIIST$313
- COBENFY$235
- DEXCOM G6 TRANSMITTER$137
- ABILIFY ASIMTUFII$121
- REXULTI$121
- Auvelity$116
- SPRAVATO$112
- AUSTEDO$111
How this compares
$51,996 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 166 | $251,785 |
| Austedo XrDeutetrabenazine | 15 | $154,942 |
| IngrezzaValbenazine Tosylate | 12 | $101,258 |
| CaplytaLumateperone Tosylate | 50 | $89,100 |
| Invega SustennaPaliperidone Palmitate | 13 | $42,736 |
| TrintellixVortioxetine Hydrobromide | 72 | $36,874 |
| RexultiBrexpiprazole | 16 | $30,109 |
| AuvelityDextromethorphan Hbr/Bupropion | 23 | $27,306 |
| VyvanseLisdexamfetamine Dimesylate | 29 | $11,303 |
| Lurasidone Hcl | 13 | $4,897 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 32 | $4,153 |
| Aripiprazole | 84 | $3,596 |
| Divalproex Sodium | 45 | $2,752 |
| Lisdexamfetamine Dimesylate | 13 | $2,592 |
| Duloxetine Hcl | 122 | $2,230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $32,794 | $251,785166 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,368 | $154,94215 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $757 | $101,25812 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,302 | $89,10050 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $685 | $48,177101 claims |
| Johnson & JohnsonInvega Sustenna | $929 | $42,73613 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,813 | $30,10916 claims |
| Axsome Therapeutics, Inc.Auvelity | $998 | $27,30623 claims |
| Almatica Pharma LLCSertraline Hcl | $1,996 | $1,115118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Austintown
- Kyle GuterbaAustintown$70K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Terri PopovitzCincinnati$161K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.